Donald J. Trump: “It is my Great Honor to announce the nomination of Chris Klomp @1klomp as ou…
Trump's Truth – Latest Posts — 2026-06-25 17:53:00 — trumpstruth.org
Donald Trump Touts Chris Klomp for HHS Deputy, Makes Dubious Claims on Drug Prices
Donald Trump announced the nomination of Chris Klomp as the next Deputy Secretary of Health and Human Services (HHS), praising Klomp as a “potential STAR” and a “Highly Successful Entrepreneur.” Trump asserted that Klomp has earned trust “everywhere” he goes, is “deeply committed to serving the AMERICAN People,” and is “doing a FANTASTIC job leading Medicare, and overseeing day-to-day operations.”
Exaggerated Claims on Drug Pricing Policy
Trump highlighted Klomp’s role in “major reforms, including my Historic MOST FAVORED NATION Drug Pricing Policy, to finally stop foreign freeriding off the backs of the American People.” He further claimed, “Our Drug Prices have come down MASSIVELY in the last year,” and stated, “It is time for other countries to pay their fair share, and they’re doing so!”
However, these assertions about drug prices are misleading. While Trump frequently touted the “Most Favored Nation” policy as a historic step to lower drug costs, the policy faced significant legal and logistical hurdles and was never fully implemented. Independent analyses and government data show that, despite Trump’s claims, U.S. drug prices did not experience a massive decline during his administration. In fact, prescription drug prices remained largely stable or increased for many Americans, and the international “freeriding” narrative has been widely disputed by health policy experts.
Praise and Promises
Trump’s statement also included sweeping praise for Klomp’s leadership and business acumen, asserting that he “puts AMERICA FIRST, and will reform Healthcare to Make America Great and Healthy Again.” Such language reflects Trump’s continued reliance on hyperbolic endorsements and promises of sweeping reform, often without substantiating evidence.
Conclusion
Trump’s announcement of Chris Klomp’s nomination as Deputy Secretary of HHS was accompanied by a series of exaggerated and misleading claims, particularly regarding drug pricing policy and the impact of his administration’s reforms. While Trump continues to frame his health care record in superlative terms, the facts do not support his assertions of “massive” drug price reductions or the effectiveness of the “Most Favored Nation” policy. As the nomination moves forward, these claims warrant careful scrutiny.